AB
Accro Bioscience
United States · Biotech · Healthtech
Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease.
Developing oral treatments for inflammatory disease
Accro Bioscience develops investigational medicines for inflammatory and autoimmune diseases. Its discovery platform targets pathways involved in regulated cell death and inflammation. Lead candidate AC-101 inhibits RIPK2, a mediator in NOD signalling, and is being developed for moderate-to-severe ulcerative colitis.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series C | $50M | Cenova Capital — Role not disclosedLAV — Role not disclosedOrbiMed — Role not disclosedOriza Holdings — Role not disclosedShenzhen Capital Group — Role not disclosedTCG Crossover — Role not disclosed |